False
Advertisement
Industry News
Fujifilm and HORIBA Develop Inline Raman System for Biomanufacturing
June 29, 2026
The system is designed for real-time monitoring of cell culture and purification, with Fujifilm reporting about a 10 percent yield improvement in antibody purification tests
2 min read
Parabilis Sets Biotech IPO Record
June 15, 2026
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
1 min read
This Week’s Biopharma News: Big Moves in Bispecifics
June 9, 2026
Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody
4 min read
This Week’s CGT News: Promising Data for In Vivo CAR T
June 8, 2026
Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts
5 min read
This Week’s Biopharma News: New Approvals, Appeals, and AI
June 2, 2026
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
6 min read
This Week’s CGT News: Base Editing Takes Aim at Cholesterol
June 1, 2026
Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M
3 min read
This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves
May 26, 2026
Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward
7 min read
This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
May 25, 2026
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
6 min read
This Week’s Biopharma News: FDA Commissioner Steps Down
May 19, 2026
Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.
3 min read
